Micafungin - Baxter International
Alternative Names: Micafungin in sodium chloride injection - Baxter InternationalLatest Information Update: 11 Feb 2025
At a glance
- Originator Baxter International
- Class Antifungals; Echinocandins; Lipoproteins
- Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bacterial infections; Candidaemia; Candidiasis; Peritonitis
Most Recent Events
- 11 Feb 2025 Baxter has patent protection for micafungin compositions in the European Union, Australia, and Spain and patent pending applications in the multiple countries worldwide prior to February 2025
- 11 Dec 2024 Launched for Bacterial infections (In adolescents, In children, In infants, In adults) in USA (IV)
- 11 Dec 2024 Launched for Candidaemia (In adolescents, In children, In infants, In adults) in USA (IV)